Using benchmarking to identify inter-centre differences in persistent ductus arteriosus treatment : can we improve outcome?

Autor: Daniel C. Vijlbrief, Peter Andriessen, Richard A. van Lingen, Esther J. S. Jansen, Koen P. Dijkman, Willem B. de Vries, Willem P. de Boode
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Male
Pediatrics
Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]
ductal ligation
Infant
Premature
Diseases

0302 clinical medicine
newborn
Ductus arteriosus
030212 general & internal medicine
Ductus Arteriosus
Patent

Netherlands
ibuprofen
Incidence (epidemiology)
Anti-Inflammatory Agents
Non-Steroidal

Gestational age
General Medicine
Ibuprofen
Prognosis
Perinatology
and Child Health
Survival Rate
Benchmarking
medicine.anatomical_structure
Echocardiography
Gestation
Female
Cardiology and Cardiovascular Medicine
Infant
Premature

medicine.drug
medicine.medical_specialty
congenital
hereditary
and neonatal diseases and abnormalities

Birth weight
Gestational Age
03 medical and health sciences
patent ductus arteriosus
indomethacin
030225 pediatrics
medicine
Journal Article
Humans
Dosing
Pediatrics
Perinatology
and Child Health

Cardiac Surgical Procedures
Ligation
Retrospective Studies
business.industry
Ductus arteriosus closure
Infant
Newborn

Infant
Low Birth Weight

Pediatrics
Perinatology and Child Health

Morbidity
business
Follow-Up Studies
Zdroj: Cardiology in the Young, 27(8), 1488. Cambridge University Press
Cardiology in the Young, 27, 1488-1496
Cardiology in the Young, 27, 8, pp. 1488-1496
ISSN: 1047-9511
Popis: ObjectiveThe aim of this study was to identify inter-centre differences in persistent ductus arteriosus treatment and their related outcomes.Materials and methodsWe carried out a retrospective, multicentre study including infants between 24+0 and 27+6 weeks of gestation in the period between 2010 and 2011. In all centres, echocardiography was used as the standard procedure to diagnose a patent ductus arteriosus and to document ductal closure.ResultsIn total, 367 preterm infants were included. All four participating neonatal ICU had a comparable number of preterm infants; however, differences were observed in the incidence of treatment (33–63%), choice and dosing of medication (ibuprofen or indomethacin), number of pharmacological courses (1–4), and the need for surgical ligation after failure of pharmacological treatment (8–52%). Despite the differences in treatment, we found no difference in short-term morbidity between the centres. Adjusted mortality showed independent risk contribution of gestational age, birth weight, ductal ligation, and perinatal centre.ConclusionsUsing benchmarking as a tool identified inter-centre differences. In these four perinatal centres, the factors that explained the differences in patent ductus arteriosus treatment are quite complex. Timing, choice of medication, and dosing are probably important determinants for successful patent ductus arteriosus closure.
Databáze: OpenAIRE